Biotech investors tend to focus on small-cap companies in search of the next big breakthrough. Still, one established player is quietly strengthening its pipeline in ways that the market has yet to fully recognize.
Gilead Sciences (GILD), valued at $147 billion, is known for its leadership in antiviral therapies, particularly its HIV franchise. However, the company is now focused on oncology innovation and next-generation cell therapy, which have long-term growth potential that the market may be overlooking.
